What the company or idea is
Corteva is a U.S.-based public company formed in March 2018 as DowDuPont’s agriculture subsidiary, focused exclusively on seeds and crop protection.
How it actually makes money
Corteva makes money selling seeds and crop protection products—including herbicides, insecticides, fungicides, and biologicals—in 110 countries.
What works
Its acquisition strategy works: the $1.2 billion purchase of Stoller Group and Symborg expanded its biologicals portfolio credibly, and its BP partnership signals credible downstream diversification beyond field crops.
What does not
Its public narrative of sustainability does not align with its commissioning of beagle testing in 2019 or its continued reliance on synthetic fungicides like flutriafol, even as it markets biological acquisitions.
What to take from it
Corteva is not a new entrant but a carved-out incumbent—structured to operate at scale, acquire selectively, and separate high-margin seed IP from lower-margin pesticide logistics, all while navigating tightening regulation and consumer scrutiny.
Is it worth your time
Yes—if you are tracking how legacy agribusinesses restructure, pivot into biologicals, and manage regulatory and reputational risk while maintaining chemical portfolios.





